Explore the full directors' dealings record of Alexandria Real Estate Equities, INC., a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Real Estate sector, Alexandria Real Estate Equities, INC. has logged 190 insider filings. Market capitalisation: €7.8bn. The latest transaction was filed on 2 June 2022 (Retenue fiscale). Among the most active insiders: Richardson Stephen. Every trade is accessible without an account.
0 of 0 declarations
Alexandria Real Estate Equities, Inc. (NYSE: ARE) is a U.S.-listed company on the NYSE in the United States and one of the best-known life science real estate investment trusts in the market. Founded in 1994 and organized as a Maryland corporation, Alexandria pioneered the life science real estate niche and has built a business model centered on owning, operating, and developing Class A/A+ laboratory and office properties tailored to biotech, pharmaceutical, medtech, research tools, and broader innovation-driven tenants. Its headquarters are in Pasadena, California, underscoring a West Coast origin while the platform now spans a national footprint. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1035443/000103544326000013/are-20251231.htm?utm_source=openai)) The company’s core strategy is to create collaborative “Megacampus™” ecosystems in leading U.S. innovation clusters, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, the Research Triangle, and New York City. This cluster-based approach is central to Alexandria’s competitive moat: the firm targets locations with dense networks of universities, hospitals, research institutions, start-ups, and large pharmaceutical companies, where demand for specialized lab-ready space is structurally higher than in conventional office real estate. Its properties are designed to meet highly technical tenant requirements, combining flexible office layouts, wet- and dry-lab infrastructure, and campus amenities that support scientific collaboration. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1035443/000103544326000014/a4q25ex991supp.htm?utm_source=openai)) From a market-position perspective, Alexandria is widely regarded as the longest-tenured and preeminent owner, operator, and developer in U.S. life science real estate. That leadership is supported by a premium asset base, irreplaceable locations, deep tenant relationships, and a development pipeline that provides visibility beyond current operating income. Public filings describe an asset base in North America that includes tens of millions of square feet of operating properties and a meaningful amount of Class A/A+ space under construction, reinforcing the company’s scale and strategic relevance. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1035443/000103544326000014/a4q25ex991supp.htm?utm_source=openai)) Recent disclosures point to a more challenging leasing environment. In its 2025 annual report, Alexandria reported operating occupancy of 90.9% at December 31, 2025, down from 94.6% a year earlier, and it projected further moderation to about 88.5% by year-end 2026, citing key lease expirations and expected downtime, particularly in Greater Boston and San Francisco. The company also noted the need for lower renewal rates and higher tenant-improvement concessions to retain or attract tenants. For investors, this suggests a normalization phase in life science real estate after a strong prior cycle, even as Alexandria retains a leading position in a niche that remains difficult to replicate. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1035443/000103544326000033/are2025.pdf?utm_source=openai))